NQO2 and Alzheimer disease: The approach of QR2 inhibition for AD treatment may provide direct or combinatory therapeutic efficacy, along with other disease modifying drugs, such as ISRIB (54), PKR (4), and PERK (55) inhibitors, for which discovery and development are ongoing.